International: +1-347-960-6455
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics to Witness Significant Growth due to Positive Clinical Results in the Coming Years

According to a new research report Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, COPD therapeutics currently exhibits a proliferating pipeline of 150+ therapeutic candidates.

COPD Therapeutics Pipeline Insights

COPD is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Factors leading to the occurrence of COPD include smoking, environmental exposures and genetic (inherited) risk. In COPD, the lungs cells lose their quality of elasticity, most of the air sacs are destroyed, and the walls of the airways become thick and inflamed and, in some cases, also become clogged by mucus.

Symptoms associated with the disease include wheezing, tightness in chest, increased breathlessness and frequent coughing. COPD is diagnosed through spirometry, which includes measurement of volume and flow of inhaled and exhaled air in the lungs. Bronchodilators, inhaled corticosteroids, and supplemental oxygen are used to treat COPD.
Also, new medications are being approved for the treatment of COPD. In November 2018, Theravance Biopharma Inc. and Mylan N.V. received U.S. Food and Drug Administration (FDA) approval for YUPELRI (revefenacin) to treat adults with COPD.

Insights on Pipeline Segments

According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered through pulmonary route. The delivery of the drug through the respiratory tract is called pulmonary drug delivery. In case of bronchodilators, this is advantageous as drug will be delivered directly to the site of action so that the effect of the drug is faster. Besides, low dose of drug can also be administered through this delivery system thus, decreasing the side effects.

Positive Clinical Trial Results are Expected to Drive the COPD Therapeutics Pipeline Advancements

The companies who are involved in developing therapeutics for COPD have shown positive clinical results in the various phases of drug development. For instance, PT010 a single inhaler, fixed-dose triple combination therapy is being developed by AstraZeneca PLC to treat patients with COPD. The top-line results from phase III KRONOS trial of PT010 demonstrated significant improvement in six out of seven lung function primary endpoints compared with dual combination therapies.

Strategic Advancements Plays a Pivotal Role in the COPD Therapeutics Development

In February 2017, Boehringer Ingelheim International GmbH collaborated with Weill Cornell Medicine to develop new treatments for COPD. The three-year collaboration combines unique understanding of chronic airway diseases of Weill Cornell Medicine’s department of genetic medicine with Boehringer Ingelheim’s expertise in the discovery and development of new therapies for respiratory diseases.

Browse report overview with detailed TOC on "Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at:

Theravance Biopharma Inc., Mylan N.V., AstraZeneca PLC, GlaxoSmithKline plc., and Chiesi Farmaceutici S.p.A. are some of the major companies involved in the development of drug candidate for the treatment of COPD.

COPD Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of COPD. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the COPD therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to COPD.